Research programme: metalloprotein inhibitors - Forge Therapeutics

Drug Profile

Research programme: metalloprotein inhibitors - Forge Therapeutics

Alternative Names: LpxC inhibitors - Forge Therapeutics; Metalloenzyme inhibitors - Forge Therapeutics

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Forge Therapeutics
  • Class Anti-infectives; Antineoplastics; Metalloproteins; Small molecules
  • Mechanism of Action Metalloprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections
  • Research Cancer

Most Recent Events

  • 30 Mar 2017 Forge Therapeutics plans a phase I trial of LpxC inhibitor antibiotic for Gram-negative infections
  • 09 Dec 2016 Forge Therapeutics and Evotec agree to co-develop metalloprotein inhibitors for Gram-negative infections
  • 26 Jul 2016 Forge Therapeutics receives phase I SBIR grant from National Institute of Allergy and Infectious Diseases for Metalloprotein inhibitors development in Gram negative infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top